Zoya Demidenko htt
페이지 정보
작성자 LincolnBoike 메일보내기 홈페이지 이름으로 검색 댓글 0건 조회 204회 작성일 26-03-25 19:17본문
<a href=https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPAMED%2C%20LLC&SearchNameOrder=RAPAN%20P050001591430&ListNameOrder=RAPAMED%20L130000429680&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord>Zoya Demidenko</a>: Researcher in Cancer Biology
<a href=https://scholargps.com/scholars/59798749410547/zoya-n-demidenko>Zoya Demidenko</a> is a prominent scholar affiliated with the Division of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she conducted research at the NIH and New York Medical College, developing a solid base in life science research.
Her academic work encompasses multiple key fields, among them the PI3K/AKT/mTOR signaling cascade, cell cycle regulation, biological aging, and malignancy science. As of now, she has written over 46 peer-reviewed publications, which have received over 4,100 references — a indicator to the significance of her findings.
One of her most notable achievements involves elucidating the mechanisms of biological cell aging. Her studies revealed that when the cellular division cycle is halted while cellular growth continues, the cells enter senescence. Crucially, <a href=https://journals.plos.org/plosone/article/authors?id=10.1371/journal.pone.0026126>Zoya Demidenko</a> established that this shift can be pharmacologically suppressed using compounds such as rapamycin.
<a href=https://pubmed.ncbi.nlm.nih.gov/22228887/>Zoya Demidenko</a> has furthermore brought substantially to tumor management investigation, particularly in the domain of cyclotherapy — a approach intended to protecting healthy cells from anticancer drugs whilst leaving malignant cells susceptible. This strategy offers major potential for diminishing the toxic effects of oncological therapy.
Throughout her professional journey, Demidenko has collaborated with leading investigators worldwide, among them Dr. Mikhail Blagosklonny. Her research is published in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, <a href=https://www.homes.com/property/38-brookins-green-dr-orchard-park-ny/de6fqfq45eme2/>Zoya Demidenko</a> ranks as a influential voice in current biomedical research, whose discoveries go on to guide our understanding of how biological cells grow old, respond to therapy, and how malignant disease can be better combated.
https://www.researchgate.net/scientific-contributions/Zoya-N-Demidenko-39445053
<a href=https://scholargps.com/scholars/59798749410547/zoya-n-demidenko>Zoya Demidenko</a> is a prominent scholar affiliated with the Division of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she conducted research at the NIH and New York Medical College, developing a solid base in life science research.
Her academic work encompasses multiple key fields, among them the PI3K/AKT/mTOR signaling cascade, cell cycle regulation, biological aging, and malignancy science. As of now, she has written over 46 peer-reviewed publications, which have received over 4,100 references — a indicator to the significance of her findings.
One of her most notable achievements involves elucidating the mechanisms of biological cell aging. Her studies revealed that when the cellular division cycle is halted while cellular growth continues, the cells enter senescence. Crucially, <a href=https://journals.plos.org/plosone/article/authors?id=10.1371/journal.pone.0026126>Zoya Demidenko</a> established that this shift can be pharmacologically suppressed using compounds such as rapamycin.
<a href=https://pubmed.ncbi.nlm.nih.gov/22228887/>Zoya Demidenko</a> has furthermore brought substantially to tumor management investigation, particularly in the domain of cyclotherapy — a approach intended to protecting healthy cells from anticancer drugs whilst leaving malignant cells susceptible. This strategy offers major potential for diminishing the toxic effects of oncological therapy.
Throughout her professional journey, Demidenko has collaborated with leading investigators worldwide, among them Dr. Mikhail Blagosklonny. Her research is published in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, <a href=https://www.homes.com/property/38-brookins-green-dr-orchard-park-ny/de6fqfq45eme2/>Zoya Demidenko</a> ranks as a influential voice in current biomedical research, whose discoveries go on to guide our understanding of how biological cells grow old, respond to therapy, and how malignant disease can be better combated.
https://www.researchgate.net/scientific-contributions/Zoya-N-Demidenko-39445053
관련링크
댓글목록
등록된 댓글이 없습니다.
